Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in <i>KRAS^G12C</i> mutant bladder cancer.

ABSTRACT: Bladder cancer is the most common malignant tumor of the urinary system. Currently, treatment strategies for bladder cancer remain limited, highlighting the urgent need to explore novel therapeutic approaches. Sotorasib, the first successful small molecule drug targeting KRAS, has been approved for treating non-small cell lung cancer (NSCLC), but it has not yet been studied in bladder cancer. Additionally, glucose metabolism-related proteins, such as GLUT1, PKM2, and LDHA are highly expressed in most bladder cancer cell lines, promoting tumor progression. KRAS^G12D mutant cells exhibit enhanced glucose uptake and glycolysis. However, little is known about whether KRAS^G12C mutant cells exhibit enhanced glucose metabolism. Various techniques, including gluc

SUBMITTER: Zhang ZR 

PROVIDER: S-EPMC11626273 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature